TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00689039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: ER tablet, administered as single and repeated doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, administered as single and repeated doses.
Study: NCT00548665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound for plaque screening
Description: Carotid ultrasound for plaque screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice for smoking cessation
Description: We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice for smoking cessation
Description: We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
Study: NCT04479358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 120mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Tocilizumab-Free Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Tocilizumab 400mg or 8mg/kg
Study: NCT01784224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves
Study: NCT01511406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
Study: NCT02246530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection into PTRCT
Description: Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial steroid bursal injection
Description: Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
Study: NCT02254603

Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
Study: NCT01303341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT04644952

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT01539824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium obuense
Description: IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
Study: NCT03750045

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jamar
Description: The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wooden box
Description: The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual environment
Description: The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
Study: NCT00593294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: 45 minutes each day for three times/week for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC - Drospirenone plus Ethynylestradiol
Description: 1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin, polyvitamins tablets
Description: Tablet of vitamin 1cp for 21 days each month for 6 months
Study: NCT02409069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (Nemos®, Cerbomed GmbH)
Study: NCT01495832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse Group
Description: The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
Study: NCT04270266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend educational sessions
Study: NCT01495832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will consume comparator foods for 12 weeks.
Study: NCT02932566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
Study: NCT04601701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Ophthalmic and Intravitreal Dexamethasone.
Description: Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
Study: NCT04270266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Attend meditation sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06207188

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT01334021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing
Study: NCT02402816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing ON
Description: MultiPoint Pacing ON

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: Implantable cardioverter-defibrillator (ICD)
Study: NCT01780311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Study: NCT04771494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power and execution speed as a function of instability experience
Description: Each subject performed 3 repetitions for the light load (40% RM; VMP \> 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position.
Study: NCT04601701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Ophthalmic.
Description: Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
Study: NCT03633370

Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted intervention including 3 components
Description: Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
Study: NCT04827069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study: NCT04555486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Intervention, drug, DCR-PHXC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Placebo comparator
Study: NCT03044509

Intervention type: DIAGNOSTIC_TEST
Intervention: Secreted cytokine assay
Description: Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Secreted cytokine assay
Description: Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Secreted cytokine assay
Description: Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Intracellular cytokine assay
Description: Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intracellular cytokine assay
Description: Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intracellular cytokine assay
Description: Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
Study: NCT03670680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Lina LibrataTM
Description: Use of the Lina LibrataTM
Study: NCT03596502

Intervention type: DRUG
Intervention: Direct oral anticoagulants (DOACs)
Description: Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.

Intervention type: DRUG
Intervention: Warfarin
Description: Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
Study: NCT03221556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement-Focused Care Coordination (EFCC)
Description: Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Education (PSE)
Description: Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
Study: NCT01805011

Intervention type: OTHER
Intervention: minimum 4 months of breastfeeding
Study: NCT04523194

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)
Description: Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)
Description: Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
Study: NCT03747549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Home Exercise
Description: Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Alone
Description: The prescribed home exercise program alone.
Study: NCT01285557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)
Description: 25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil/cisplatin (control arm)
Description: 5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Study: NCT03754725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone pill
Description: 1000 mg of deferiprone (oral) BID (15 mg/Kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will receive placebo orally

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Montreal Cognitive Assessment
Description: Neurocognitive assessment, lower score indicates lower cognitive level

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: Neurocognitive assessment, lower score indicates lower cognitive level
Study: NCT01746836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood draws.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Starting dose: 30 mg by mouth once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Surveys completed.
Study: NCT02772419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benralizumab
Description: SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benralizumab
Description: SC administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration
Study: NCT03079921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine
Description: Physiologic receptor blockade (α1-receptor).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Physiologic receptor blockade (β2-receptor).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL bag of Normal Saline Solution (NSS).
Study: NCT03479814

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT-SIB plus sequential IG-RT boost
Study: NCT03353688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: Deep brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: Deep brain stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: Deep brain stimulation
Study: NCT04125836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029 (octreotide subcutaneous depot)
Description: Octreotide subcutaneous depot for monthly injections in acromegaly patients
Study: NCT02110719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Study: NCT04386317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.